AT385201B - Verfahren zur herstellung einer antiinflammatorischen ophthalmischen loesung - Google Patents

Verfahren zur herstellung einer antiinflammatorischen ophthalmischen loesung

Info

Publication number
AT385201B
AT385201B AT0464382A AT464382A AT385201B AT 385201 B AT385201 B AT 385201B AT 0464382 A AT0464382 A AT 0464382A AT 464382 A AT464382 A AT 464382A AT 385201 B AT385201 B AT 385201B
Authority
AT
Austria
Prior art keywords
producing
ophthalmic solution
inflammatory ophthalmic
inflammatory
solution
Prior art date
Application number
AT0464382A
Other languages
English (en)
Other versions
ATA464382A (de
Original Assignee
Kaken Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharma Co Ltd filed Critical Kaken Pharma Co Ltd
Publication of ATA464382A publication Critical patent/ATA464382A/de
Application granted granted Critical
Publication of AT385201B publication Critical patent/AT385201B/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT0464382A 1981-12-24 1982-12-22 Verfahren zur herstellung einer antiinflammatorischen ophthalmischen loesung AT385201B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56214189A JPS58126810A (ja) 1981-12-24 1981-12-24 抗炎症眼科用液剤およびその製法

Publications (2)

Publication Number Publication Date
ATA464382A ATA464382A (de) 1987-08-15
AT385201B true AT385201B (de) 1988-03-10

Family

ID=16651708

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0464382A AT385201B (de) 1981-12-24 1982-12-22 Verfahren zur herstellung einer antiinflammatorischen ophthalmischen loesung

Country Status (12)

Country Link
US (1) US4474811A (de)
EP (1) EP0082921B1 (de)
JP (1) JPS58126810A (de)
AT (1) AT385201B (de)
AU (1) AU549419B2 (de)
CA (1) CA1182751A (de)
CH (1) CH652598A5 (de)
DE (1) DE3274187D1 (de)
DK (1) DK570482A (de)
ES (1) ES515455A0 (de)
IE (1) IE54467B1 (de)
ZA (1) ZA829410B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (de) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmazeutische Zusammensetzung und ihre Verwendung
JPS5929616A (ja) * 1982-08-10 1984-02-16 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS60184013A (ja) * 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd 点眼剤
US5266563A (en) * 1984-06-11 1993-11-30 Biomatrix, Inc. Hyakyribate-poly (ethylene oxide) mixtures
US4629623A (en) * 1984-06-11 1986-12-16 Biomatrix, Inc. Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
JP2764261B2 (ja) * 1987-03-17 1998-06-11 リ−ドケミカル株式会社 外用消炎鎮痛剤
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
IT1241928B (it) * 1990-05-18 1994-02-01 S I F I Societa Ind Farmaceuti Composizione oftalmica per l'uso nel mantenimento della midriasi oculare
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5362758A (en) * 1992-09-18 1994-11-08 Pfizer Inc. Ophthalmic piroxicam solution
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
US5382599A (en) * 1993-10-13 1995-01-17 Allergan, Inc. Method of inhibiting protozoan growth in eye care products using a polyvalent cation chelating agent
US5977180A (en) * 1994-07-11 1999-11-02 Pate; David W. Anandamide analog compositions and method of treating intraocular hypertension using same
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US6797722B2 (en) * 2002-05-03 2004-09-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases
AU2016201834A1 (en) * 2002-07-30 2016-04-14 Omeros Corporation Ophthalmologic irrigation solutions and method
US20040072809A1 (en) 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
ES2772252T3 (es) * 2014-03-21 2020-07-07 Epitech Group S P A Preparaciones oftálmicas, intraarticulares o intravesicales que contienen N-acil-etanolaminas
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
JPS5634618A (en) * 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
JPS5646838A (en) * 1979-09-27 1981-04-28 Mitsubishi Yuka Yakuhin Kk 2- 2-fluoro-4-biphenylyl propionic acid-cyclodextrin clathrate compound
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1359987A (en) * 1970-10-12 1974-07-17 Boots Co Ltd 2-substituted biphenylyl propionic acids
US4202988A (en) * 1977-03-30 1980-05-13 American Cyanamid Company Prostenoic acids and esters
JPS5528904A (en) * 1978-08-18 1980-02-29 Mitsubishi Petrochem Co Ltd Preparation of biphenyl derivative
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
US4379792A (en) * 1980-10-30 1983-04-12 Merck & Co., Inc. Anti-inflammatory composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230724A (en) * 1979-07-16 1980-10-28 Allergan Pharmaceuticals, Inc. Method of treating vascularization of the eye with Flurbiprofen
JPS5634618A (en) * 1979-08-30 1981-04-06 Ota Seiyaku Kk Production of flurbiprofen preparation
JPS5646838A (en) * 1979-09-27 1981-04-28 Mitsubishi Yuka Yakuhin Kk 2- 2-fluoro-4-biphenylyl propionic acid-cyclodextrin clathrate compound
JPS56123912A (en) * 1980-03-05 1981-09-29 Nitto Electric Ind Co Ltd Drug-containing tape preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JP- ABSTRACT & JP 56034618 A *
JP- ABSTRACT & JP 56046838 A *
JP- ABSTRACT & JP 56123912 A *

Also Published As

Publication number Publication date
US4474811A (en) 1984-10-02
IE823020L (en) 1983-06-24
DK570482A (da) 1983-06-25
ZA829410B (en) 1983-10-26
EP0082921A1 (de) 1983-07-06
CA1182751A (en) 1985-02-19
IE54467B1 (en) 1989-10-25
ES8401849A1 (es) 1984-01-01
JPS58126810A (ja) 1983-07-28
AU549419B2 (en) 1986-01-23
EP0082921B1 (de) 1986-11-12
DE3274187D1 (en) 1987-01-02
AU9175282A (en) 1983-06-30
CH652598A5 (de) 1985-11-29
ES515455A0 (es) 1984-01-01
ATA464382A (de) 1987-08-15

Similar Documents

Publication Publication Date Title
AT385201B (de) Verfahren zur herstellung einer antiinflammatorischen ophthalmischen loesung
AT380476B (de) Verfahren zur herstellung von chinazolinderivaten
AT382780B (de) Verfahren zur herstellung einer insulinloesung
AT382150B (de) Verfahren zur herstellung von neuen 3-amino-2-oxo-azetidin-1-sulfonsaeurederivaten
ATA148982A (de) Verfahren zur herstellung einer analgetisch wirkenden zusammensetzung
ATA423783A (de) Verfahren zur herstellung von beta-hydroxybuttersaeurederivaten
AT381091B (de) Verfahren zur herstellung von neuen ergolinderivaten
DE3650051D1 (de) Verfahren zur Herstellung einer Roentgenlinse.
AT385661B (de) Verfahren zur herstellung einer stabilen humanplasma-proteinfraktion
AT379399B (de) Verfahren zur herstellung von optisch aktiven penemen
AT380477B (de) Verfahren zur herstellung von neuen spirothiazolidindion-derivaten
AT388160B (de) Verfahren zur herstellung von isobutyrylfluorid
AT377207B (de) Verfahren zur herstellung von schaftmeisseln
AT376879B (de) Verfahren zur herstellung einer injektionsloesung
ATA328780A (de) Verfahren zur herstellung acylaminobenzoesaeurecerivaten
AT377264B (de) Verfahren zur herstellung von neuen nitrosoharnstoffderivaten
AT381318B (de) Verfahren zur herstellung von neuen nitrosoharnstoffderivaten
AT378186B (de) Verfahren zur herstellung von cimetidin
AT384477B (de) Verfahren zur herstellung einer leuchte
ATA263781A (de) Verfahren zur herstellung von beta-amidoethyl-ether-derivaten
ATA535281A (de) Verfahren zur herstellung von phenoxyisobutters|ureestern
ATA328581A (de) Verfahren zur herstellung von 1-phenoxy-3-amino- 2-propanolen
AT378180B (de) Verfahren zur herstellung von adrenochrom
AT372938B (de) Verfahren zur herstellung von ketoaminen
DD160149A3 (de) Verfahren zur herstellung von brenzkatechin

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee